Influenza vaccine + pneumococcal vaccine
Influenza vaccine + pneumococcal vaccine has been studied in 2 papers since 2023: 1 observational study in people, 1 review; 1 in the past year. The newest paper, Mar 30, 2026: “Effectiveness of influenza and pneumococcal vaccination in frail older adults”.
2 papers study it2 findingsUpdated
“The combination of pneumococcal and influenza vaccines was associated with a 35% reduction in pneumonia hospitalization (HR 0.65; 95%CI 0.51-0.83).”
None of its findings points the other way.
- 2 independent labs in 2 countries
- Funder: Association Nationale de la Recherche et de la Technologie
- Humans1
What is Influenza vaccine + pneumococcal vaccine linked with?
2Studies link Influenza vaccine + pneumococcal vaccine with 2 measures, most often pneumonia-related hospitalization (1 study) and cardiovascular disease (1).
Pneumonia-related hospitalization
downin humans1HR 0.65
1 study
Pneumonia-related hospitalization
downin humans1HR 0.65
Influenza vaccine + pneumococcal vaccine is linked with a lower risk of pneumonia-related hospitalization in humans (HR 0.65; 95%CI 0.51-0.83).
“The combination of pneumococcal and influenza vaccines was associated with a 35% reduction in pneumonia hospitalization (HR 0.65; 95%CI 0.51-0.83).”
Humansn = 12,268
Effectiveness of influenza and pneumococcal vaccination in frail older adults
Revista da Associacao Medica Brasileira (1992)
Cardiovascular disease
downin humans1
1 study
Cardiovascular disease
downin humans1
Influenza vaccine + pneumococcal vaccine lowers the risk of cardiovascular disease in humans.
“dual influenza and pneumococcal vaccination was associated with lower risks of some cardiovascular events (stroke, congestive heart failure, ischemic heart disease, and myocardial infarction)”
Review
GeroScience